ArticleVirulence2025
Intratumorally specific microbial-derived lipopolysaccharide contributes to non-small cell lung cancer progression.
Article in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Comment on "Intratumorally specific microbial-derived lipopolysaccharide contributes to non-small cell lung cancer progression".Virulence · 2026Article
- Article
- Review
- Label-Free Target Discovery Strategy for Natural Active Products.Biomolecules · 2026Review
- Crosstalk between the microbiome and immune microenvironment in the pathogenesis and treatment of thyroid carcinoma: a narrative review.Frontiers in immunology · 2026Review
- Microbiome and metabolite signatures for cirrhosis to HCC risk stratification: progress, controversies, and gaps.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an emerging component of the tumor microenvironment (TME), the intratumoural microbiota imperceptibly influences the progression of various human malignancies. However, the critical intratumoural microbiota and its role in non-small cell lung cancer (NSCLC) progression have not been fully elucidated. Here, we used high-throughput sequencing and clinical samples analysis to identify the relationship between intratumoural bacteria and NSCLC progression. The results showed that significant abnormalities in the intratumoural microbiota of NSCLC. Specifically, the relative abundance of gram-negative bacteria in tumor was significantly increased, and network analysis revealed that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.